Marksans Pharma Limited Statistics
Want to see IN:MARKSANS full AI Analyst Report?
Marksans Pharma Limited (MARKSANS) Stock Statistics & Valuation Metrics
Total Valuation
Marksans Pharma Limited has a market cap or net worth of INR 137.72B. The enterprise value is INR 140.18B.
- Market Cap
- INR 137.72B
- Enterprise Value
- INR 140.18B
Share Statistics
Marksans Pharma Limited has 453,163,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 453,163,760
- Owned by Insiders
- ―
- Owned by Institutions
- 6.41%
Financial Efficiency
Marksans Pharma Limited’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 11.10%.
- Return on Equity (ROE)
- 0.14
- Return on Assets (ROA)
- 0.11
- Return on Invested Capital (ROIC)
- 11.10%
- Return on Capital Employed (ROCE)
- 0.15
- Revenue Per Employee
- 17.51M
- Profits Per Employee
- 2.48M
- Employee Count
- 1,685
- Asset Turnover
- 0.76
- Inventory Turnover
- 1.85
Valuation Ratios
The current PE Ratio of Marksans Pharma Limited is 24.98. Marksans Pharma Limited’s PEG ratio is 0.42.
- PE Ratio
- 24.98
- PS Ratio
- 4.13
- PB Ratio
- 4.20
- Price to FCF
- 7006.23
- Price to Operating Cash Flow
- 186.09
- PEG Ratio
- 0.42
Income Statement
In the last 12 months, Marksans Pharma Limited had revenue of 29.51B and earned 4.18B in profits. Earnings per share was 9.22.
- Revenue
- 29.51B
- Gross Profit
- 11.57B
- Operating Income
- 5.05B
- Pretax Income
- 5.61B
- Net Income
- 4.18B
- EBITDA
- 6.03B
- Earnings Per Share (EPS)
- 9.22
Cash Flow
In the last 12 months, operating cash flow was 751.86M and capital expenditures -731.89M, giving a free cash flow of 19.97M billion.
- Operating Cash Flow
- 751.86M
- Free Cash Flow
- 19.97M
- Free Cash Flow per Share
- 0.04
Dividends & Yields
Marksans Pharma Limited pays an annual dividend of INR 0.80, resulting in a dividend yield of 0.30%
- Dividend Per Share
- INR 0.80
- Dividend Yield
- 0.30%
- Payout Ratio
- 10.06%
- Free Cash Flow Yield
- 0.01%
- Earnings Yield
- 4.00%
Stock Price Statistics
- Beta
- 0.96
- 52-Week Price Change
- 64.67%
- 50-Day Moving Average
- 319.02
- 200-Day Moving Average
- 246.03
- Relative Strength Index (RSI)
- 46.64
- Average Volume (3m)
- 225.87K
Important Dates
Marksans Pharma Limited upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- Aug 01, 2025
Financial Position
Marksans Pharma Limited as a current ratio of 5.17, with Debt / Equity ratio of 11.36%
- Current Ratio
- 5.17
- Quick Ratio
- 3.32
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.48
- Interest Coverage Ratio
- 20.92
Taxes
In the past 12 months, Marksans Pharma Limited has paid 1.40B in taxes.
- Income Tax
- 1.40B
- Effective Tax Rate
- 0.25
Enterprise Valuation
Marksans Pharma Limited EV to EBITDA ratio is 16.67, with an EV/FCF ratio of 6707.45.
- EV to Sales
- 3.95
- EV to EBITDA
- 16.67
- EV to Free Cash Flow
- 6707.45
- EV to Operating Cash Flow
- 178.16
Balance Sheet
Marksans Pharma Limited has INR 9.91B in cash and marketable securities with INR 0.00 in debt, giving a net cash position of INR 9.91B billion.
- Cash & Marketable Securities
- INR 9.91B
- Total Debt
- INR 0.00
- Net Cash
- INR 9.91B
- Net Cash Per Share
- INR 21.87
- Tangible Book Value Per Share
- INR 67.36
Margins
Gross margin is 40.99%, with operating margin of 19.99%, and net profit margin of 16.51%.
- Gross Margin
- 40.99%
- Operating Margin
- 19.99%
- Pretax Margin
- 22.13%
- Net Profit Margin
- 16.51%
- EBITDA Margin
- 23.70%
- EBIT Margin
- 20.58%
Analyst Forecast
The average price target for Marksans Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 24.20%
- EPS Growth Forecast
- 59.18%
Scores
- Smart Score
- ―
- AI Score
- 70
